AI assistant
USCOM LIMITED — Investor Presentation 2016
Jun 20, 2016
65979_rns_2016-06-20_a979f70d-8f66-4cc0-8d6c-ed96e7bc24a9.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Uscom (UCM) – Global Medical Devices
Global growth June 2016
==> picture [842 x 118] intentionally omitted <==
Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO
The Measure of Life
Disclaimer
This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.
While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA.
The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.
Uscom
“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”
Uscom – Medical devices the experts use
Summary
-
Non-invasive cardiovascular pulmonary device manufacturer
-
World leading technologies
-
Global partners, nearing profitability (
±$3m revenue) -
Rapid growth (+40% for 4 years), before transformational revenue and partnerships
-
Uscom BP+ and SpiroSonic for market and revenue FY 2017
-
Transformational partnership with China CIIC – $65m over 5 years
-
Growth foundations set for the coming decade
-
Annual results imminent
-
Unrecognised investor value
-
Uscom Annual report
Business Background
-
Premium noninvasive cardiovascular and pulmonary monitoring devices
-
Addressing the growing threat of superbugs, heart failure, hypertension and asthma
-
Validated, clinically accepted, cost and life saving devices with critical applications
-
Aggressive global growth strategy
-
IP protected and FDA, CE and CFDA regulatory approvals
-
Uscom BP+ and SpiroSonic for market FY 2017
-
Transformational partnerships evolving
==> picture [691 x 214] intentionally omitted <==
----- Start of picture text -----
Corporate Board & Management Financials
� ASX listed (UCM) � Rob Phillips, Chairman & CEO � Sales +59% 2015
� Headquartered in Sydney � Sheena Jack, Director � Revenue +48% 2015
� (HCF, Moneytime Health) ($2+m)
Market cap of $28m
� 108m shares on issue � Christian Bernecker, Director � Cash consumption - $1m
� Rob Phillips, Founder and (Stream) � Gross Margins ~ 78%
� David He, Director (J&J, McKinseys) �
CEO, holds 18% of Cash ~ $2.7m
company � Nick Schicht, General Manager
----- End of picture text -----
- Uscom Annual report
Strategic growth
==> picture [40 x 31] intentionally omitted <==
Three world leading technologies merged under one operating entity Debt free acquisitions – scrip, raising and operations Rapidly strengthening balance sheet Acquisitive, strategic and diversified entity Scientific, operational and strategic synergy New product suites developed and funded from operations UK entity founded, Hungarian manufacturing integrated Preparing to market and volume manufacture BP+ and SpiroSonic New revenue streams - BP+ and SpiroSonic in 2017
Uscom – Devices the experts use
Uscom Recognition
Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards
“A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy”
==> picture [397 x 51] intentionally omitted <==
==> picture [219 x 97] intentionally omitted <==
Uscom – Devices the experts use
Products and Market
Multiple high fidelity noninvasive digital medical devices
Fluid, Sepsis
& Heart Failure
-
US 1.3bn market[*]
-
CAGR of 7.6%[*]
-
CE, FDA, TGA, CFDA
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [5 x 4] intentionally omitted <==
==> picture [4 x 4] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
Hypertension & Vascular Health
COPD
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [4 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
==> picture [5 x 5] intentionally omitted <==
& Asthma
-
US 1.7bn market[*]
-
US 400m market[*]
-
CAGR of 11.5%[*]
-
CAGR of 6.5%[*]
-
CE, FDA, TGA
-
CE, TGA, FDA
USCOM 1A
BP+
Cardiac Output Monitoring Blood Pressure Monitoring
SpiroSonic Pulmonary Monitoring
==> picture [141 x 113] intentionally omitted <==
==> picture [125 x 127] intentionally omitted <==
- Source: MedTech Insight; Transparency Market Research
Uscom – Devices the experts use
Products - USCOM 1A
Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology
Accurate cardiac output
Cardiac stroke volume Systemic vascular resistance Left + right heart measurement
==> picture [308 x 250] intentionally omitted <==
Works with all other hospital equipment Intuitive touch screen Real time data Platform technology with multiple uses
Non invasive, real time, beat-to-beat haemodynamics
Uscom – Devices the experts use
Products - Uscom BP+
Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension
-
FDA, CE Mark, TGA approvals
-
• Supra-systolic Oscollometry
-
• Reliable and
-
• accurate
-
• Central and
-
• Brachial BP
-
• Replaces sub-systolic methods (cuff)
-
Home or clinic
-
• PPW Analysis
-
• Results in
-
30 seconds
-
• No training required
-
• Platform technology with multiple uses
Stand alone, non invasive, accurate, compact system with BP+Reporter
Uscom – Devices the experts use
Products - Uscom SpiroSonic
Asthma, COPD, Occupational Lung Disease and drug compliance monitoring
-
High fidelity digital ultrasonic spirometry
-
Multi-path ultrasonic sensing
==> picture [276 x 78] intentionally omitted <==
==> picture [137 x 72] intentionally omitted <==
-
FDA, CE, and TGA approvals
-
Reliable and accurate
-
Auto calibration
==> picture [276 x 78] intentionally omitted <==
==> picture [137 x 72] intentionally omitted <==
-
Research, home and clinic
-
Wireless transmission
-
SpiroReporter analysis software
==> picture [189 x 59] intentionally omitted <==
-
FloFree tube – low resistance
-
Software guided examination and report
-
Simple disinfection
-
Platform sensors with medical and industrial applications
Stand alone, non invasive, accurate, compact system with SpiroReporter
Uscom – Devices the experts use
Big Data
Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors
==> picture [90 x 47] intentionally omitted <==
- Software analytics
==> picture [90 x 47] intentionally omitted <==
-
Telemetric signals
-
Cloud based processing/diagnosis
-
Personalised clinical advice
==> picture [87 x 89] intentionally omitted <==
-
Medication and dosage
-
Serial monitoring
-
Multiple measures
-
Home care market
-
Subscription service model
==> picture [143 x 137] intentionally omitted <==
-
Global partner opportunities – China, US, Euro
-
Multiple software providers – few hardware providers
Stand alone, wireless, accurate, compact, digital devices
Uscom – Devices the experts use
New - tSpiro Uscom selling technologies others are researching High fidelity telemetric spirometer The future for asthma and COPD
-
CE, FDA and TGA. CFDA in train
-
US revenue (more than 400)
-
Software analytics
-
Telemetric signals to cloud via iphone
-
Cloud based processing/diagnosis
-
Connecting patients to clinicians
-
Personalised clinical advice - medication and dosage
-
Serial monitoring
-
Multiple measures
-
Home care market
-
Capital and subscription revenue
-
Global partners – China, US, Euro
-
Multiple software providers – few hardware providers
Resapp (RAP) – Cap $240m, Adherium (ADR) – Cap $77m, Uscom (UCM) – Cap $28m
New Series
Improved diagnosis, management and monitoring of pulmonary diseases tSpirometers - high fidelity telemetric pulmonary monitoring
For launch FY 2017
Uscom – Devices the experts use
Regulatory
Uscom is preparing a new generation of products for regulatory approval across multiple jurisdictions for marketing in 2017
| USCOM 1A | BP+ | Uscom BP+ | Thor | SpiroSonic | |
|---|---|---|---|---|---|
| CE (Europe) |
✓ |
✓ |
Preparation | ✓ |
Preparation |
| FDA (USA) |
✓ |
✓ |
Preparation | ✓ |
Preparation |
| CFDA (China) |
✓ |
- | Preparation | - | Preparation |
| TGA (Aus) |
✓ |
✓ |
Preparation | ✓ |
Preparation |
==> picture [143 x 136] intentionally omitted <==
==> picture [93 x 94] intentionally omitted <==
==> picture [106 x 65] intentionally omitted <==
Uscom – Devices the experts use
BioTechnology Leader
==> picture [210 x 107] intentionally omitted <==
Uscom BP+ Thor Granted 12 21 3 Pendin 4 1 1 g
Patents - Real IP, real value, product pipeline
Uscom – Devices the experts use
De-Risked Technology
Featured in 500+ peer reviewed publications and presentations
==> picture [98 x 117] intentionally omitted <==
==> picture [102 x 125] intentionally omitted <==
==> picture [96 x 113] intentionally omitted <==
==> picture [94 x 110] intentionally omitted <==
==> picture [93 x 111] intentionally omitted <==
==> picture [93 x 112] intentionally omitted <==
==> picture [81 x 107] intentionally omitted <==
Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia, Pulmonary hypertension, Nurse outreach, Organ procurement, Haemodialysis, Neonates, infants, Children etc……..
Uscom – Devices the experts use
Multi-Products
Three world leading product ranges entering profit phase
==> picture [772 x 320] intentionally omitted <==
----- Start of picture text -----
Global Profit
Concept Product Pilot Validation Regulatory Revenue
Distribution FY17
USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓
Uscom BP+ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓
SpiroSonic ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Investment to Profit
----- End of picture text -----
IP transformed into profit
Revenue Targets
==> picture [675 x 420] intentionally omitted <==
----- Start of picture text -----
SpiroSonic – FY 2017
Total Revenue
20,000,000
18,000,000
16,000,000 BP+ - FY 2017
14,000,000
12,000,000
SpiroSonic
$ 10,000,000
BP+
USCOM
8,000,000 USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
----- End of picture text -----*
==> picture [400 x 21] intentionally omitted <==
----- Start of picture text -----
$20m revenue by 2020 = 5 year CAGR of 58%
----- End of picture text -----
The Future
Value Cascade
==> picture [624 x 33] intentionally omitted <==
==> picture [759 x 279] intentionally omitted <==
----- Start of picture text -----
Products Sales Operations Opportunities
USCOM 1A
New appointments Global operations Share price growth
Uscom BP+
Current distribution Increased products Dividend
BP+Reporter
Thor distribution Increased scale Transaction
SpiroSonic
Completion of
New distribution Cost effective
Capital RaiseSmart
manufacture
Mobile Major partners
Tube Re-imbursement Revenue growth
Tele Profitability
US market focus
SpiroReporter
----- End of picture text -----
Converting off balance sheet assets to revenue.
-
Uscom Aus
-
Uscom UK
Global Operations
-
Uscom Budapest
-
Uscom USA
==> picture [160 x 18] intentionally omitted <==
----- Start of picture text -----
5. Uscom Shanghai
----- End of picture text -----
2 •[•] • •[• •] • •• 3
[• ] • • • • •[•] •
[•] • •
[•] • 4 •• • •• • 5 • • • • •
==> picture [129 x 113] intentionally omitted <==
----- Start of picture text -----
•
1
----- End of picture text -----
Key Markets 1/5. AsiaPAC 2/3. Europe 4. Nth America
• • •[•] •
Focus FY 2017
Asia – Establish CIIC US – BP+ and SpiroSonic release Global tSpiro partnerships
China Growth
==> picture [462 x 384] intentionally omitted <==
----- Start of picture text -----
China Health Expenditure as % of GDP
7.9
6.5
5.1 5.0 5.1 [5.4]
4.6 [4.84.8 4.7 4.7]
4.6 4.4 [4.6]
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2018E 2020E
----- End of picture text -----
David He joins UCM Board Formerly J&J China, McKinsey Shanghai
China Health Spend (USD) GDP=12,000,000,000,000 Health=5.4%=648,000,000,000 Objective=12%=1,400,000,000,000 Growth(+6.6%)=$792,000,000,000 Uscom China Targets (USD) Population = 1.35b 3 provinces < 10% pop = $10m 31 Provinces = 100% 10 x current UCM revenue = $10m 2 new products = $20m Total revenue China = $30m USD
Uscom positioning to grow with China - $30m pa revenue target
News - Uscom CIIC China
==> picture [479 x 228] intentionally omitted <==
==> picture [105 x 64] intentionally omitted <==
Five year importation and wholesale agreement with Shanghai CIIC Science and ≈ Technology Development Corp targeted to generate USD$48.2m ( A$65m) in sales. CIIC S&T – State owned company CIIC revenue – $10b USD, Med Device Division $250m USD
Uscom – Medical devices the experts use
CIIC China
==> picture [105 x 64] intentionally omitted <==
“We plan to make Uscom one of the leading medical device brands in China over the next five years.”
Daniel Sun, Head of BD and Marketing, Shanghai CIIC Science and Technology, Medical Device division
Shareholder value, if targets achieved - $1.40 per share. ($13m sales, $6m costs, profit $7m, PE x 20, 108m shares)
Uscom – Medical devices the experts use
Increasing recognition
==> picture [154 x 116] intentionally omitted <==
==> picture [334 x 94] intentionally omitted <==
==> picture [327 x 186] intentionally omitted <==
==> picture [225 x 64] intentionally omitted <==
==> picture [334 x 95] intentionally omitted <==
Alan Kohler Peter Switzer Fox TV
CNBC Asia
With improved operational performance has come increased media and international investor interest
Uscom – Medical devices the experts use
Increasing recognition
==> picture [423 x 216] intentionally omitted <==
==> picture [423 x 217] intentionally omitted <==
==> picture [340 x 47] intentionally omitted <==
With improved operational performance has come increased media and international investor interest
The Australian, 5-3-16 Sarah-Jane Tasker
Current objectives
-
Realise CIIC targets
-
Maintain USCOM 1A growth
-
Deliver BP+, BP+Reporter, SpiroSonic and SpiroReporter to worldwide markets (products, regulatory and manufacturing)
-
Continue partnership discussions
-
Distributors with high reach and reputation
-
Develop specific application distribution – eHealth, maternal health, paediatric sepsis, etc.
-
Consolidate global entity and operations
-
• Manage rapid growth
Uscom – Medical devices the experts use
Operational risks
-
Global medical markets unpredictable
-
Product development/regulatory slower and more costly than expected
-
Distribution slow to achieve revenue goals and integrate new products
-
Costs for acquisitions, product development and production in advance of revenue
-
Competition risks and patent breaches – difficult to predict and monitor competitors
-
Complexity of operating in multiple jurisdictions – China, US, UK, Hungary, Australia
-
Preserving current revenue growth as new products developed for market
-
International accounting & auditing expensive, complex and time consuming
-
New product lines and new marketing – time to learn
-
Transitioning Budapest to volume manufacture
Uscom – Medical devices the experts use
UCM – Growth trend
A blue sky story with de-risked operations
==> picture [524 x 378] intentionally omitted <==
----- Start of picture text -----
UCM Revenue and Income
$2,500,000
40
$2,039,426
$2,000,000 35
30
$1,500,000 $1,377,716
25
$1,010,942 20
$1,000,000
15
12
10
$500,000
5
$0 0
2013 2014 2015 2013
Current revenue from USCOM 1A
BP+ and SpiroSonic revenue in FY 2017
----- End of picture text -----
UCM Distribution Agreements
==> picture [303 x 254] intentionally omitted <==
----- Start of picture text -----
40 38
35
30
27
25
20
15
12
10
5
0
2013 2014 2015
----- End of picture text -----
UCM – Growth trend
Revenue and Income
==> picture [376 x 259] intentionally omitted <==
----- Start of picture text -----
$2,900,000
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015 2016
----- End of picture text -----*
==> picture [388 x 291] intentionally omitted <==
2016 - Revenue + cash receipts continue to rise (40 ± % for 4 years) Share price +77%
Transformational CIIC deal and new products yet to be accounted by market
Right company, right time…..
- Estimate
Profitability?
Revenue rising 40% YOY for last 4 years Margins 60-80% 2016 YOY cash receipts rising: Q1 up 133%, H1 up 71%, Q3 up 112% Q3 cash outflow $55k (near breakeven) 2016 costs include once off costs: Thor acquisition ($700k)
UCM Quarterly Cash Receipts
==> picture [351 x 253] intentionally omitted <==
----- Start of picture text -----
700,000
600,000
500,000
400,000
$
300,000
200,000
100,000
0
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
13 13 14 14 14 14 15 15 15 15 16 16 16
----- End of picture text -----
Integration of Thor - audit, restructure and reporting Regulatory preparation for BP+ and SpiroSonic Marketing and distribution Transformational CIIC deal for $15m pa (6m costs - $7m pa profit) New global deals in discussion
Right company, right time…..
Right Sector - Long Term Growth
ASX 10 yr CAGR % pa
==> picture [490 x 294] intentionally omitted <==
----- Start of picture text -----
14.0
12.1
12.0
10.0
8.0
6.0
3.5
% 4.0
2.0
0.1 0.0
0.0
S&P 200 Financial NAB Materials BHP RMD Healthcare
-2.0 Index (Mining) Index
Index
-2.4
-4.0
-4.5 -4.3
-6.0
----- End of picture text -----
UCM sales growth 2014 – 67% 2015 – 59%
-
1[st] Feb 2006 – 1[st] Feb 2016
-
Exclusive of dividends
Healthcare, right sector…..
Right Time for Growth
Revenue Growth % pa
==> picture [605 x 357] intentionally omitted <==
----- Start of picture text -----
60
50
40
Uscom
30
Resmed
%
CSL
20
Cochlear
10
0
2013 2014 2015
-10
----- End of picture text -----
Right company, right time…..
UCM outperforms market
==> picture [547 x 375] intentionally omitted <==
==> picture [221 x 57] intentionally omitted <==
2016 year to date performance…..
BellDirect 20[h] June 2016
Uscom
Value investment ✓ Experienced management ✓ Strong underlying business ✓ Strong growth phase ✓ ✓ Invested in growth Premium global markets ✓ Diversified and lifesaving technologies ✓ Aggressive global growth strategy ✓ Two new product ranges for market in the next 12mths ✓ Right time – 2016 results imminent ✓
Uscom – Medical devices the experts use
Uscom
“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”
Uscom – Medical devices the experts use
Uscom (UCM) – Global Medical Devices
Global Growth June 2016
==> picture [842 x 118] intentionally omitted <==
Thank You
Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO
Uscom – Medical devices the experts use
USCOM 1A Competitive Advantage
| Method | Manufacturer | Technology | Rel+Rep | Non- invasive |
Simple | Cost | Portable | SV beat to beat |
|---|---|---|---|---|---|---|---|---|
| USCOM 1A | Uscom | Doppler | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| BioZ | Samsung | BioImpedance | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ |
| NiCOM | Cheetah | BioReactance | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ |
| Nexfin | Bmeye | APP | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ |
| CardioQ | Deltex | Doppler | ✓ | ✗ | ✓ | ✗ | ✓ | ✗ |
| LiDCO | LiDCO | LiCl dilutio +APP | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| LiDCOrapid | LiDCO | APP | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ |
| PiCCO (mod Tx + PP) |
Pulsion | APP | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| FloTrac | Edwards | APP | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| PAC (Tx) | Many | Thermodilution | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
Testimonials
“This machine is saving lives, there are no two ways about it.”
Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia
“USCOM has changed the way I look at the cardiovascular status of my patients.
It’s part of the initial shock evaluation and monitored regularly thereafter…. USCOM has now been established as the standard of care.”
Dr Akash Deep, Director of Paediatric ICU, King's College Hospital, London
“The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. The device has the potential to change the way we approach management of sepsis, heart failure and hypertension.”
Professor Malcolm West, Cardiologist, Mayne Professor of Medicine at The University of Queensland School of Medicine, Brisbane, Australia and Uscom Medical Advisory Board Member.
“I have used USCOM for over 5 years now on our very sick children, and use it to guide management. We are now beginning multi-centre, global research which will define the way USCOM is used in Paediatric Departments across the world.”
Dr Joe Brierley, Consultant Intensivist, Great Ormond Street Hospital for Sick Children, London, UK.
“The USCOM device is really good; I use it in all my aneasthetics. I think there should be one on every ICU bed and on every anaesthetic patient.”
Dr Steve Woodford, Consultant Anaesthetist, circulatory researcher at Australian School of Advanced Medicine, and Uscom Investor,
“To parents and doctors this machine, USCOM, is priceless. This machine is thought to have saved baby Abbie’s life.
BBC Documentary “New machine helps save babies life”, 2010, Nottingham Children’s Hospital
Uscom – Medical devices the experts use
BP+ Competitive Advantage
==> picture [94 x 95] intentionally omitted <==
| Uscom BP+ | TensioMed | BPLab | IEM | Centron | AtCor |
|---|---|---|---|---|---|
| Australia | Hungary | Russia | Germany | UK | Australia |
| USD 3,500 | USD 6,000 | USD 7,000 | USD 7,000 | USD 6,300 | USD 20,000 |
| 1 min | 2 min | 2 min | 2 min | 1 min | 1 min |
| Stand-alone | ABP, needs computer | ABP, needs computer | ABP, needs computer | Stand-alone | Needs computer |
| CE, FDA, TGA | CE | CE | CE, FDA | CE | CE, FDA |
| Aortic + brachial waveform |
Central systolic BP | Rough waveform | Rough waveform | Rough waveform | Rough waveform |
| Physical model | Statistical regression | Transfer function | Transfer function | Transfer function | Transfer function |
Uscom – Medical devices the experts use
Why ?
Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars
==> picture [651 x 296] intentionally omitted <==
BP+ is on the international space station
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/ eurojeartj/eht565
SpiroSonic Competitive Advantage
==> picture [149 x 47] intentionally omitted <==
==> picture [94 x 77] intentionally omitted <==
==> picture [98 x 73] intentionally omitted <==
==> picture [80 x 86] intentionally omitted <==
==> picture [75 x 75] intentionally omitted <==
==> picture [88 x 87] intentionally omitted <==
==> picture [75 x 77] intentionally omitted <==
==> picture [99 x 76] intentionally omitted <==
| Uscom SpiroSonic |
Welch Allyn | Schiller | Sibelmed | Vitalograph | MIR | Carefusion | NDD |
|---|---|---|---|---|---|---|---|
| Australia | USA | Switzerland | Spain | USA | Italy | USA | Switzerland |
| SpiroSonic | SpiroPerfect | Spirovit SP-1 | Dataspir Touch | Pneumotrac | Spirodoc | Microloop | EasyOne PLus |
| USD 1,890 | USD 2,100 | USD 1,850 | USD 2,300 | USD 2,030 | USD 1,580 | USD 2,180 | USD 1,990 |
| Dual Path Ultrasound |
Diff Pressure | Diff Pressure | Turbine | Diff Pressure | Turbine | Turbine | Single Path Ultrasound |
| Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable |
Multiple iterations |
Multiple iterations |
Multiple iterations |
Multiple iterations |
Multiple iterations Conssumable turbines |
Multiple iterations |
Accurate Consumable tube |
Uscom – Medical devices the experts use
CPT Codes and Re-Imbursement
| Product | Measure | Region | Code | Price(AUD) | Status |
|---|---|---|---|---|---|
| Uscom BP+ | Central BP | USA | 93050 | $25.60 | S* |
| USCOM 1A | Cardiac Output | USA | 76999 | $107.00 | S** |
| Cardiac Output | China | 310701023 | $44.00 | ✓ | |
| Cardiac Output | China | 220600010 | $13.50 + $2.50 measure |
✓ | |
| Cardiac Output | Australia | TBD | TBD | S** | |
| Uscom Thor | Spirometry | USA | 94010 | $51.43 | ✓ |
| Spirometry | USA | 94060 | $87.14 | ✓ | |
| Spirometry | USA | 94070 | $87.00 | ✓ | |
| Spirometry | USA | 94375 | $57.14 | ✓ | |
| Spirometry | Australia | 11506 | $20.55 | ✓ | |
| Spirometry | Australia | 11509 | $35.65 | ✓ | |
| Spirometry | Australia | 11512 | $61.75 | ✓ |
S[*] Subject to Software modification and FDA notification
S[**] Under submission
TBD –To be determined